{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:41:11Z","timestamp":1788262871846,"version":"build-2803163510"},"reference-count":33,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Background: Asciminib (Scemblix\u00ae) is approved for the first-line treatment of adult patients with chronic myeloid leukemia in the chronic phase at 40 mg twice daily (BID) and 80 mg once daily (QD) or 200 mg BID for patients harboring the T315I mutation. Objectives: (1) Extrapolate the DDI magnitude as the perpetrator or victim of other drugs and the effect of organ impairment to untested doses; (2) Predict clinically untested DDI scenarios. Methods: Asciminib is primarily cleared by cytochrome P450 (CYP)3A4, UDP-glucuronosyltransferases (UGT)2B7, UGT2B17, UGT1A3\/4, and the breast-cancer-resistance protein (BCRP). In vitro asciminib is an inhibitor of several CYP, UGT enzymes, and transporters and is an inducer of CYP1A2 and CYP3A4. Clinical DDI studies assessed asciminib 40 mg BID as a perpetrator on CYP-sensitive substrates. Additional studies evaluated the impact of strong CYP3A4 perpetrators and imatinib on a single 40 mg dose of asciminib. Hepatic and renal impairment studies were also conducted at the 40 mg dose. A nonlinear whole-body physiologically based pharmacokinetic (PBPK) model was developed and verified for asciminib as a CYP3A4, UGT, and BCRP substrate and a perpetrator of several CYP and UGT enzymes. Results: This PBPK model was applied in lieu of clinical pharmacology studies to support the new drug application of Scemblix\u00ae and to bridge data from 40 mg BID to the 80 mg QD and 200 mg BID dose regimens. Conclusions: The PBPK predictions informed the drug product label and are estimated to have replaced at least 10 clinical studies.<\/jats:p>","DOI":"10.3390\/pharmaceutics17101266","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T14:50:38Z","timestamp":1758898238000},"page":"1266","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Physiologically Based Pharmacokinetic Modeling and Simulations in Lieu of Clinical Pharmacology Studies to Support the New Drug Application of Asciminib"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2586-3577","authenticated-orcid":false,"given":"Ioannis","family":"Loisios-Konstantinidis","sequence":"first","affiliation":[{"name":"Pharmacokinetic Sciences, Translational Medicine, Biomedical Research, Novartis, 4056 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Huth","sequence":"additional","affiliation":[{"name":"Pharmacokinetic Sciences, Translational Medicine, Biomedical Research, Novartis, 4056 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1033-2716","authenticated-orcid":false,"given":"Matthias","family":"Hoch","sequence":"additional","affiliation":[{"name":"Pharmacokinetic Sciences, Translational Medicine, Biomedical Research, Novartis, 4056 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4966-7645","authenticated-orcid":false,"given":"Heidi J.","family":"Einolf","sequence":"additional","affiliation":[{"name":"Pharmacokinetic Sciences, Translational Medicine, Biomedical Research, Novartis, East Hanover, NJ 07936, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S336","DOI":"10.1016\/S2152-2650(21)01785-7","article-title":"CML-417: ASCEMBL Phase 3 Health-Related Quality of Life (HRQL) Comparison of Asciminib and Bosutinib for Patients with Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated with 2 or More Tyrosine Kinase Inhibitors (TKI)","volume":"21","author":"Mauro","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/s40262-024-01411-1","article-title":"Dose Justification for Asciminib in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia with and Without the T315I Mutation","volume":"63","author":"Combes","year":"2024","journal-title":"Clin. Pharmacokinet."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1080\/00498254.2019.1594449","article-title":"Disposition of Asciminib, a Potent BCR-ABL1 Tyrosine Kinase Inhibitor, in Healthy Male Subjects","volume":"50","author":"Tran","year":"2020","journal-title":"Xenobiotica"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1111\/cts.13252","article-title":"Pharmacokinetic Drug Interactions of Asciminib with the Sensitive Cytochrome P450 Probe Substrates Midazolam, Warfarin, and Repaglinide in Healthy Participants","volume":"15","author":"Hoch","year":"2022","journal-title":"Clin. Transl. Sci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1111\/cts.13285","article-title":"Pharmacokinetics of Asciminib in the Presence of CYP3A or P-Gp Inhibitors, CYP3A Inducers, and Acid-Reducing Agents","volume":"15","author":"Hoch","year":"2022","journal-title":"Clin. Transl. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/cpdd.1019","article-title":"Pharmacokinetics of Asciminib When Taken With Imatinib or With Food","volume":"11","author":"Hoch","year":"2022","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1002\/jcph.1926","article-title":"Pharmacokinetics of Asciminib in Individuals With Hepatic or Renal Impairment","volume":"61","author":"Hoch","year":"2021","journal-title":"J. Clin. Pharmacol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1007\/s40262-024-01428-6","article-title":"Clinical Pharmacology of Asciminib: A Review","volume":"63","author":"Hoch","year":"2024","journal-title":"Clin. Pharmacokinet."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1124\/dmd.108.026252","article-title":"Comparison of Different Algorithms for Predicting Clinical Drug-Drug Interactions, Based on the Use of CYP3A4 in Vitro Data: Predictions of Compounds as Precipitants of Interaction","volume":"37","author":"Fahmi","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1124\/dmd.118.080523","article-title":"Abundance of Phase 1 and 2 Drug-Metabolizing Enzymes in Alcoholic and Hepatitis C Cirrhotic Livers: A Quantitative Targeted Proteomics Study","volume":"46","author":"Prasad","year":"2018","journal-title":"Drug Metab. Dispos."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/cpt.2125","article-title":"Physiologically-Based Pharmacokinetic Modeling in Renal and Hepatic Impairment Populations: A Pharmaceutical Industry Perspective","volume":"110","author":"Heimbach","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1016\/j.xphs.2021.01.029","article-title":"Predicting Oral Absorption for Compounds Outside the Rule of Five Property Space","volume":"110","author":"Huth","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.1021\/acs.molpharmaceut.7b00198","article-title":"Validation of Dissolution Testing with Biorelevant Media: An OrBiTo Study","volume":"14","author":"Mann","year":"2017","journal-title":"Mol. Pharm."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s40262-022-01148-9","article-title":"Population Pharmacokinetics of Asciminib in Tyrosine Kinase Inhibitor-Treated Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic and Acute Phases","volume":"61","author":"Li","year":"2022","journal-title":"Clin. Pharmacokinet."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s11095-006-9135-x","article-title":"Kinetic Considerations for the Quantitative Assessment of Efflux Activity and Inhibition: Implications for Understanding and Predicting the Effects of Efflux Inhibition","volume":"24","author":"Kalvass","year":"2007","journal-title":"Pharm. Res."},{"key":"ref_16","unstructured":"European Medicines Agency (2024, July 26). Investigation of Drug Interactions\u2014Scientific Guideline. Available online: https:\/\/www.ema.europa.eu\/en\/investigation-drug-interactions-scientific-guideline."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1023\/A:1018943613122","article-title":"Physiological Parameters in Laboratory Animals and Humans","volume":"10","author":"Davies","year":"1993","journal-title":"Pharm. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"676","DOI":"10.2174\/138920007782109733","article-title":"Prediction of Intestinal First-Pass Drug Metabolism","volume":"8","author":"Yang","year":"2007","journal-title":"Curr. Drug Metab."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/psp4.12449","article-title":"Recommendations for the Design of Clinical Drug\u2013Drug Interaction Studies With Itraconazole Using a Mechanistic Physiologically-Based Pharmacokinetic Model","volume":"8","author":"Chen","year":"2019","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1124\/dmd.112.048017","article-title":"Autoinhibition of CYP3A4 Leads to Important Role of CYP2C8 in Imatinib Metabolism: Variability in CYP2C8 Activity May Alter Plasma Concentrations and Response","volume":"41","author":"Filppula","year":"2013","journal-title":"Drug Metab. Dispos."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","article-title":"Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure","volume":"381","author":"Hughes","year":"2019","journal-title":"New Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood.2020009984","article-title":"A Phase 3, Open-Label, Randomized Study of Asciminib, a STAMP Inhibitor, vs Bosutinib in CML after 2 or More Prior TKIs","volume":"138","author":"Mauro","year":"2021","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/cpt.37","article-title":"Physiologically Based Pharmacokinetic Modeling in Drug Discovery and Development: A Pharmaceutical Industry Perspective","volume":"97","author":"Jones","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/psp4.12479","article-title":"Consideration of a Credibility Assessment Framework in Model-Informed Drug Development: Potential Application to Physiologically-Based Pharmacokinetic Modeling and Simulation","volume":"9","author":"Kuemmel","year":"2020","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1124\/dmd.110.036103","article-title":"Critique of the Two-Fold Measure of Prediction Success for Ratios: Application for the Assessment of Drug-Drug Interactions","volume":"39","author":"Guest","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1002\/jps.21759","article-title":"Development of a Novel Method for Predicting Human Volume of Distribution at Steady-State of Basic Drugs and Comparative Assessment with Existing Methods","volume":"98","author":"Poulin","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejps.2017.03.002","article-title":"Substrate and Method Dependent Inhibition of Three ABC-Transporters (MDR1, BCRP, and MRP2)","volume":"103","author":"Pedersen","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/bdd.2022","article-title":"TKI Combination Therapy: Strategy to Enhance Dasatinib Uptake by Inhibiting Pgp- and BCRP-Mediated Efflux","volume":"37","author":"Bae","year":"2016","journal-title":"Biopharm. Drug Dispos."},{"key":"ref_29","unstructured":"U.S. Food and Drug Administration (FDA) (2025, July 30). Scemblix Multi-Discipline Review, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2021\/215358Orig1s000,Orig2s000MultidisciplineR.pdf."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"105593","DOI":"10.1016\/j.ejps.2020.105593","article-title":"Inhibition of ABCG2\/BCRP-Mediated Transport\u2013Correlation Analysis of Various Expression Systems and Probe Substrates","volume":"156","author":"Kurunczi","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_31","unstructured":"U.S. Food and Drug Administration (FDA) (2025, July 30). FDA Approves Asciminib for Philadelphia Chromosome-Positive Chronic Myeloid Leukemia, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/215358s009lbl.pdf."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1124\/dmd.120.000055","article-title":"Considerations from the Innovation and Quality Induction Working Group in Response to Drug-Drug Interaction Guidance from Regulatory Agencies: Guidelines on Model Fitting and Recommendations on Time Course for In Vitro Cytochrome P450 Induction Studies Including Impact on Drug Interaction Risk Assessment","volume":"49","author":"Wong","year":"2021","journal-title":"Drug Metab. Dispos."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/cpt.917","article-title":"Harnessing Meta-Analysis to Refine an Oncology Patient Population for Physiology-Based Pharmacokinetic Modeling of Drugs","volume":"103","author":"Schwenger","year":"2018","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/10\/1266\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T14:52:49Z","timestamp":1758898369000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/10\/1266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":33,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["pharmaceutics17101266"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics17101266","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]}}}